Wells Fargo & Company Atara Biotherapeutics, Inc. Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.44 - $1.22 $2,034 - $5,640	4,623 Added 13.07%	39,988 $27,000
Q4 2023 Feb 09, 2024	SELL	$0.23 - $1.74 $201 - $1,527	-878 Reduced 2.42%	35,365 $18,000
Q3 2023 Nov 13, 2023	SELL	$1.41 - $2.31 $18,738 - $30,699	-13,290 Reduced 26.83%	36,243 $53,000
Q2 2023 Aug 15, 2023	SELL	$1.5 - $3.04 $111,153 - $225,270	-74,102 Reduced 59.94%	49,533 $79,000
Q1 2023 May 12, 2023	BUY	$2.8 - $5.46 $310,478 - $605,432	110,885 Added 869.69%	123,635 $358,000
Q4 2022 Feb 13, 2023	SELL	$2.85 - $5.18 $16,504 - $29,997	-5,791 Reduced 31.23%	12,750 $41,000
Q3 2022 Nov 14, 2022	SELL	$2.85 - $8.73 $36,921 - $113,097	-12,955 Reduced 41.13%	18,541 $70,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $41,206 - $86,454	8,786 Added 38.69%	31,496 $246,000
Q1 2022 May 16, 2022	SELL	$8.44 - $16.89 $257,048 - $514,401	-30,456 Reduced 57.28%	22,710 $211,000
Q4 2021 Feb 14, 2022	SELL	$14.7 - $19.89 $49,494 - $66,969	-3,367 Reduced 5.96%	53,166 $837,000
Q3 2021 Nov 15, 2021	SELL	$11.99 - $17.9 $1.2 Million - $1.8 Million	-100,411 Reduced 63.98%	56,533 $1.01 Million
Q2 2021 Aug 16, 2021	SELL	$12.89 - $16.58 $268,936 - $345,925	-20,864 Reduced 11.73%	156,944 $2.44 Million
Q1 2021 May 13, 2021	SELL	$14.0 - $20.72 $286,076 - $423,392	-20,434 Reduced 10.31%	177,808 $2.55 Million
Q4 2020 Feb 09, 2021	BUY	$12.67 - $26.23 $264,169 - $546,895	20,850 Added 11.75%	198,242 $3.89 Million
Q3 2020 Nov 05, 2020	SELL	$11.92 - $15.87 $9,023 - $12,013	-757 Reduced 0.42%	177,392 $2.3 Million
Q2 2020 Aug 13, 2020	BUY	$7.53 - $14.93 $932,492 - $1.85 Million	123,837 Added 228.01%	178,149 $2.6 Million
Q1 2020 May 14, 2020	BUY	$5.69 - $17.78 $309,035 - $965,667	54,312 New	54,312 $462,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

2.89M

Call Options Held

Put Options Held

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.08B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account